EUVIMEDEUVIMED entdecken
Open Access

Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence

Kevin X Liu iD, Kee-Young Shin iD, Manisha Thakuria iD, Jonathan D Schoenfeld iD, Roy B Tishler iD, Ann W Silk iD, Charles H Yoon iD, Elliott Fite iD, Danielle N Margalit iD

Cancer · 2024

DOI: 10.1002/cncr.35507 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Kevin X Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Brigham & Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Neoplasm Recurrence, Local, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Institutes of Health Loan Repayment Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Serum antibodies to the Merkel oncoprotein (AMERK) are detectable in approximately 50% of patients with Merkel cell carcinoma (MCC) and can be used to monitor for recurrence. The objective of this study was to characterize AMERK levels in patients receiving curative‐intent radiation therapy (RT) for MCC and identify associations between AMERK and recurrence.

Methods

This was a retrospective study of patients with MCC who had baseline AMERK measurements before they received curative‐intent RT from 2010 to 2020. Event‐free survival (EFS) was calculated using the Kaplan–Meier method and Cox regression. The cumulative incidence of MCC‐related recurrence (CIMR) was analyzed with death as a competing risk and the Gray test.

Results

The authors identified 88 patients who had baseline AMERK measurements, including 52 (59%) with detectable levels. AMERK positivity was associated with younger median age (67.8 vs. 72.0 years; p = .02) and tumor site ( p = 0.02), with lower rates for those who had disease in the head/neck region (17.3% vs. 44.4%). EFS (71.3% vs. 60.4%; p = .30) and CIMR (24.4% vs. 39.6%; p = .23) were more favorable in AMERK‐positive patients. Two patients had recurrences in the RT field, and both were AMERK‐negative at baseline. The median time to AMERK nadir after RT was 11.2 months; and, in a 6‐month post‐RT landmark analysis, the proportion of patients who were AMERK‐positive who became negative or who had levels that decreased by ≥50% were not associated with EFS (87.1% vs. 85.0%; p = .90) or CIMR (12.9% vs. 15.0%; p = .62).

Conclusions

Positive AMERK baseline levels were correlated with younger age at MCC diagnosis and nonhead and neck tumor location, possibly related to the distribution of viral etiology. A specific post‐RT AMERK decline correlating with EFS could not be identified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellNeoplasm Recurrence, LocalSkin NeoplasmsHumansMaleFemaleAgedRetrospective StudiesMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

Merkel cell carcinoma (MCC)Merkel cell oncoprotein antibodies (AMERK)antibodyradiation therapyrecurrence

Autor:innen und Institutionen

  • Department of Radiation Oncology, Brigham & Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Merkel Cell Carcinoma Center of Excellence, Dana-Farber/Brigham & Women's Cancer Center, Boston, Massachusetts, USA.
  • Department of Dermatology, Brigham & Women's Hospital, Boston, Massachusetts, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Division of Surgical Oncology, Department of Surgery, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts, USA.

ORCID-Profile: Kevin X Liu, Kee-Young Shin, Manisha Thakuria, Jonathan D Schoenfeld, Roy B Tishler, Ann W Silk, Charles H Yoon, Elliott Fite, Danielle N Margalit

Förderung

  • NCI NIH HHS
  • National Institutes of Health Loan Repayment Program

Zitieren

APA

Liu, K. X., Shin, K. Y., Thakuria, M., Schoenfeld, J. D., Tishler, R. B., Silk, A. W., Yoon, C. H., Fite, E., & Margalit, D. N. (2024). Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence. Cancer. https://doi.org/10.1002/cncr.35507

Vancouver

Liu KX, Shin KY, Thakuria M, Schoenfeld JD, Tishler RB, Silk AW, et al. Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence. Cancer. 2024. doi:10.1002/cncr.35507

BibTeX
@article{Liu2024,
  author = {Liu, Kevin X and Shin, Kee-Young and Thakuria, Manisha and Schoenfeld, Jonathan D and Tishler, Roy B and Silk, Ann W and Yoon, Charles H and Fite, Elliott and Margalit, Danielle N},
  title = {Changes in Merkel cell oncoprotein antibodies after radiation therapy in curatively treated Merkel cell carcinoma and association with recurrence},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35507}
}
Kostenlos starten →